English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background.  In this retrospective analysis we assessed the role of [ 18 F]-FACBC-PET/CT in the prostatic cancer staging.  Procedure.  30 first [ 18 F]-FACBC-PET/CT images of 26 patients (68.1 ± 5.8 years) were analyzed. PET/CT findings were compared with PSA concentrations, with PSA doubling times (PDT), and with correlative imaging.  Results.  On 16 [ 18 F]-FACBC (53.3%) scans, 58 metabolically active lesions were found.  12 (20.7%) lesions corresponding to the local relapse were found in prostate/prostate bed and seminal vesicles, 9 (15.5%) lesions were located in regional lymph nodes, 10 (17.2%) were located in distal lymph nodes, and 26 (44.8%) metabolically active lesions were found in the skeleton. In one case, focal uptake was found in the brain, confirmed further on MRI as meningioma. The mean S-PSA level in patients with positive [ 18 F]-FACBC findings was 9.5 ± 16.9   μ  g/L (0.54–69   μ  g/L) and in patients with negative [ 18 F]-FACBC findings was 1.96 ± 1.87   μ  g/L (0.11–5.9   μ  g/L), but the difference was not statistically significant. However, the PSA doubling time (PDT) in patients with positive findings was significantly shorter than PDT in patients with negative findings: 3.25 ± 2.09 months (0.3–6 months) versus 31.2 ± 22.02 months (8–84 months),  P  < 0.0001. There was a strong positive correlation between PSA value and number of metabolically active lesions ( R  = 0.74) and a negative correlation between PDT and number of metabolically active lesions ( R  = −0.56). There was a weak negative correlation between PDT and SUV max⁡  ( R  = −0.30).  Conclusion.  According to our preliminary clinical experience, [ 18 F]-FACBC-PET may play a role in  in vivo  restaging of an active prostate cancer, especially in patients with a short S-PSA doubling time.

biomed research international

Preliminary Clinical Experience of<i>trans</i>-1-Amino-3-(18)F-fluorocyclobutanecarboxylic Acid (<i>anti</i>-(18)F-FACBC) PET/CT Imaging in Prostate Cancer Patients

Preliminary Clinical Experience oftrans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic Acid (anti-(18)F-FACBC) PET/CT Imaging in Prostate Cancer Patients